Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Nanoparticle Albumin-Bound Rapamycin and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03660930
Recruitment Status : Recruiting
First Posted : September 7, 2018
Last Update Posted : February 28, 2022
Aadi Bioscience, Inc.
Information provided by (Responsible Party):
University of Washington

Brief Summary:
This phase I/II trial studies the side effects and best dose of nanoparticle albumin-bound rapamycin and how well it works when given together with pazopanib hydrochloride in treating participants with nonadipocytic soft tissue sarcomas that has spread to other places in the body (advanced). Nanoparticle albumin-bound rapamycin and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Condition or disease Intervention/treatment Phase
Advanced Soft Tissue Sarcoma Locally Advanced Soft Tissue Sarcoma Metastatic Soft Tissue Sarcoma Drug: Nanoparticle Albumin-Bound Rapamycin Drug: Pazopanib hydrochloride Phase 1 Phase 2

Detailed Description:

OUTLINE: This is a phase I, dose-escalation study of nanoparticle albumin-bound rapamycin followed by a phase II study.

Participants receive ABI-009 intravenously (IV) on days 1 and 8 and pazopanib hydrochloride orally (PO) daily on days 1-21. Cycles repeat every 21 days until unequivocal clinical disease progression, unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at the patient's discretion.

After completion of study treatment, participants are followed up at 30 days, then every 12 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 57 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study of ABI-009 (Nab-Rapamycin) With Pazopanib (VOTRIENT®) in Patients With Advanced Nonadipocytic Soft-Tissue Sarcomas
Actual Study Start Date : April 1, 2019
Estimated Primary Completion Date : February 28, 2024
Estimated Study Completion Date : February 28, 2025

Arm Intervention/treatment
Experimental: Treatment (ABI-009, pazopanib)
Participants receive nanoparticle albumin-bound rapamycin IV on days 1 and 8 and pazopanib hydrochloride PO daily on days 1-21. Courses repeat every 21 days until unequivocal clinical disease progression, unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at the patient's discretion.
Drug: Nanoparticle Albumin-Bound Rapamycin
Given IV
Other Names:
  • Nab-Rapamycin
  • ABI-009

Drug: Pazopanib hydrochloride
Given PO
Other Name: Votrient

Primary Outcome Measures :
  1. The maximum-tolerated dose (MTD) of nab-rapamycin in combination with pazopanib (Phase I) [ Time Frame: Up to 21 days ]
    Will be estimated using dose-limiting toxicities (DLTs). Will use a Simon's minimax design.

  2. Progression-free survival (PFS) rate (Phase II) [ Time Frame: At 3 months ]
    Will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. Will be assessed via descriptive statistics.

Secondary Outcome Measures :
  1. Incidence of adverse events profile (Phase I and II) [ Time Frame: Up to 28 days after last dose ]
    Will be based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0

  2. Median overall survival (OS) (Phase II) [ Time Frame: At 12 months ]
    Will be summarized using Kaplan-Meier (KM) analysis and descriptive statistics.

  3. Median PFS (Phase II) [ Time Frame: At 6 months ]
    Will be summarized using KM analysis and descriptive statistics.

  4. Disease control rate (complete response [CR] +partial response [PR] + stable disease [SD]) (Phase II) [ Time Frame: Up to 2 years ]
    Will be based on RECIST v1.1. Will be evaluated by computed tomography (CT) imaging.

  5. Duration of response (Phase II) [ Time Frame: Up to 2 years ]
    Will be evaluated by CT imaging.

  6. Objective response rate (CR + PR) (Phase II) [ Time Frame: Up to 2 years ]
    Will be based on RECIST v1.1. Will be evaluated by CT imaging.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must have a histologically confirmed diagnosis of non-adipocytic STS that is either metastatic or locally advanced and for which curative therapy is not available, surgery is not a recommended option, and pazopanib treatment is indicated.
  • Subjects must have one or more measurable target lesions by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1, assessed via computed tomography (CT) scan or magnetic resonance imaging (MRI).
  • Clinical or radiological progression or failure due to toxicity on at least 1 prior regimen of systemic treatment for advanced disease. Subjects may not have received more than 4 prior lines of systemic therapy (no more than 2 prior therapies may be combination cytotoxic therapies). Neo-adjuvant/adjuvant/maintenance treatments are not included for this criterion.
  • Last dose of prior therapy must have been completed a minimum of 14 days prior to start of protocol therapy. All ongoing toxicities related to prior therapy must be resolved or grade 1 (except alopecia).

    * NOTE: Toxicities from prior therapy that have resolved with sequalae (e.g. hypothyroidism) and are asymptomatic or well-controlled are not exclusionary.

  • Total bilirubin =< upper limit of normal (ULN) mg/dL (Subjects with known Gilbert's syndrome and a total bilirubin =< 3 mg/dl are permitted to enroll to phase 2/expansion phase only with investigator approval).
  • Aspartate aminotransferase (AST) =< 2.5 x ULN and alanine aminotransferase (ALT) =< 2.5 x ULN.
  • Serum creatinine =<1.5 x ULN (If serum creatinine is > 1.5 mg/dL, calculated creatinine clearance > 50 mL/min using the Cockcroft-Gault formula may be included).
  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L.
  • Platelet count >= 100,000/mm^3 (100 x 10^9/L).
  • Hemoglobin >= 9 g/dL.
  • Serum triglyceride =< 300 mg/dL.
  • Serum cholesterol =< 350 mg/dL.
  • Baseline cardiac left ventricular ejection fraction (LVEF) within institutional limits of normal (by echocardiogram or multigated acquisition [MUGA] study).
  • Baseline electrocardiogram with corrected QT (QTc) < 480 millisecond (Bazett's).
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Male or non-pregnant and non-breast feeding female:

    • Females of child-bearing potential must agree to use highly effective contraception without interruption from initiation of therapy and while on study medication and have a negative serum pregnancy test (beta human chorionic gonadotropin [beta-hCG]) result at screening and agree to ongoing pregnancy testing during the course of the study, and at the end of study treatment. A highly effective method of contraception is defined as one that results in a low failure rate (that is, < 1% per year), when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, or a vasectomized partner.
    • Male patients must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study.
  • Life expectancy of > 3 months, as determined by the investigator.
  • Ability to understand and sign informed consent.
  • Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures.

Exclusion Criteria:

  • Soft tissue sarcomas with biology or defined treatments for which pazopanib is not indicated, including adipocytic STS, gastrointestinal stromal tumors (GIST), or Kaposi's sarcoma.
  • Previously received an mTOR inhibitor or angiogenesis inhibitor.
  • Known active uncontrolled or symptomatic central nervous system (CNS) metastases. A subject with controlled and asymptomatic CNS metastases may participate in this study. As such, the patient must have completed any prior treatment for CNS metastases >= 28 days (including radiotherapy and/or surgery) prior to start of treatment in this study and should not be receiving chronic corticosteroid therapy for the CNS metastases.
  • Subjects with hemoptysis, central nervous system hemorrhage or gastrointestinal hemorrhage within the last 6 months prior to treatment are excluded due to pazopanib-associated risk of bleeding.
  • Subjects with severe hepatic impairment and active gastrointestinal bleeding.
  • Uncontrolled serious medical or psychiatric illness.
  • Subjects with a currently active second malignancy other than non-melanoma skin cancers, carcinoma in situ of the cervix, resected incidental prostate cancer, or other adequately treated carcinoma-in-situ are ineligible. Subjects are not considered to have a currently active malignancy if they have completed therapy and are free of disease for >= 1 year).
  • Recent infection requiring systemic anti-infective treatment that was completed =< 14 days prior to enrollment (with the exception of uncomplicated urinary tract infection or upper respiratory tract infection).
  • No clinically significant gastrointestinal abnormalities including malabsorption syndrome, major resection of the stomach or small bowel that could affect the absorption of study drug, active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation, history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to beginning study treatment.
  • Uncontrolled diabetes mellitus as defined by hemoglobin A1C (HbA1c) > 8% despite adequate therapy.
  • Subjects with unstable coronary artery disease, myocardial infarction, or an arterial thromboembolic event during preceding 6 months.
  • Subjects with history of interstitial lung disease and/or pneumonitis, or pulmonary hypertension.
  • Use of strong inhibitors and inducers of CYP3A4 within the 14 days prior to receiving the first dose of ABI-009. Additionally, use of any known CYP3A4 substrates with narrow therapeutic window (such as fentanyl, alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, terfenadine) within the 14 days prior to receiving the first dose of ABI-009.
  • Active hepatitis B or hepatitis C infection.
  • Systemic immunosuppression, including human immunodeficiency virus (HIV) positive status with or without acquired immunodeficiency syndrome (AIDS).
  • Subjects with history of intestinal perforations, fistula, hemorrhages and/or hemoptysis =< 6 months prior to first study treatment.
  • Subjects with hypercholesterolemia receiving ongoing treatment with simvastatin.
  • Subjects who have had major surgery within 28 days of planned initiation of protocol therapy, or patients who have/have had wound dehiscence, or other open wounds (including diabetic or infectious wounds) with active wound complications.
  • Subjects with prior history of severe hypersensitivity (grade 3 or higher) to any known drug excipients, including anaphylaxis to human serum albumin.
  • Subjects with uncontrolled hypertension, defined as an average systolic blood pressure (SBP) >= 140 mmHg or an average diastolic blood pressure (DBP) >= 90 mmHg despite best supportive care measures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03660930

Layout table for location contacts
Contact: Roxanne Moore 206-606-6425

Layout table for location information
United States, Washington
Fred Hutch/University of Washington Cancer Consortium Recruiting
Seattle, Washington, United States, 98109
Contact: Roxanne Moore    206-606-6425   
Principal Investigator: Lee Cranmer, MD         
Sponsors and Collaborators
University of Washington
Aadi Bioscience, Inc.
Layout table for investigator information
Principal Investigator: Lee Cranmer, MD Fred Hutch/University of Washington Cancer Consortium
Layout table for additonal information
Responsible Party: University of Washington Identifier: NCT03660930    
Other Study ID Numbers: RG1718053
10015 ( Other Identifier: Fred Hutch/University of Washington Cancer Consortium )
NCI-2018-01624 ( Registry Identifier: NCI )
First Posted: September 7, 2018    Key Record Dates
Last Update Posted: February 28, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs